Genetic Testing for Neurodegenerative Diseases

📖 Wiki Page

diagnostic1017 wordssynced 2026-04-02

Genetic Testing Workflow

flowchart TD A["Clinical Indication<br/>Family History"] --> B["Genetic Counseling"] B --> C{"Testing Method"} C --> D["SNP Arrays"] C --> E["Targeted Panels"] C --> F["Whole Exome"] C --> G["Whole Genome"] D --> D1["CNV Detection<br/>Risk SNPs"] E --> E1["Known Genes<br/>AD/PD/ALS"] F --> F1["All Coding Regions"] G --> G1["Complete Sequence<br/>Non-coding"] D1 --> H["Sequencing"] E1 --> H F1 --> H G1 --> H H --> I["Bioinformatics Analysis"] I --> J["Variant Calling"] J --> K["Variant Annotation"] K --> L{"Interpretation"} L --> M["Pathogenic"] L --> N["VUS"] L --> O["Benign"] M --> P["Clinical Action"] N --> Q["Reclassification"] O --> R["Negative Result"] P --> S["Family Screening"] Q --> S style A fill:#0a1929,stroke:#333,color:#e0e0e0 style M fill:#3b1114,stroke:#333,color:#e0e0e0 style O fill:#9f9,stroke:#333,color:#0d0d1a

Introduction

Overview

...

Genetic Testing Workflow

Mermaid diagram (expand to render)

Introduction

Overview

Genetic testing has become an increasingly important tool in the diagnosis, risk assessment, and clinical management of neurodegenerative diseases[@goldman2023]. With the identification of hundreds of genes implicated in conditions ranging from Alzheimer's Disease to amyotrophic lateral sclerosis, genetic testing now plays a critical role in confirming diagnoses, identifying presymptomatic carriers, guiding family planning decisions, and — increasingly — determining eligibility for targeted therapies such as tofersen for SOD1-mutant ALS and anti-amyloid antibodies for APOE ε4 carriers[@apostolova2024]. [@goldman2023]

Types of Genetic Tests

Single-Gene Testing

Single-gene testing targets a specific gene when a particular condition is strongly suspected based on clinical presentation and family history. This approach is most appropriate for: [@apostolova2024]

Huntington's Disease: Testing the huntingtin-protein gene for CAG trinucleotide repeat expansions (>36 repeats confirms diagnosis)
SOD1-ALS: Testing for SOD1 mutations in familial ALS, now therapeutically actionable with tofersen
Spinocerebellar ataxias: Testing specific ATXN1, ATXN2, ATXN3, or ATXN7 genes for repeat expansions

Multigene Panel Testing

Multigene panels simultaneously analyze 20–500+ genes associated with a particular disease category. Current panels include: [@koriath2021]

Dementia panels: Genes including app-protein, psen1, psen2, tau-protein, GRN, and c9orf72 for comprehensive dementia genetic screening
Movement disorder panels: Genes including LRRK2, GBA, PARK7, PINK1, and PRKN for Parkinson's and related disorders
Ataxia and spastic paraplegia groups: Genes including ATXN1, ATXN2, ATXN3, ATXN7, SPAST, and Isp55 for hereditary ataxia evaluation

These panels offer a balance between breadth and cost-effectiveness, making them suitable for patients with heterogeneous clinical presentations[@koriath2021]. [@bisbrewer2024]

Whole-Exome and Whole-Genome Sequencing

WES and WGS provide the most comprehensive genetic analysis, covering all protein-coding regions (WES) or the entire genome including non-coding variants (WGS). These approaches are particularly useful for: [@rohilla2019]

Patients with atypical or undiagnosed neurodegenerative presentations
Cases where targeted panels have been uninformative
Research settings investigating novel disease genes
Detection of structural variants, copy number changes, and repeat expansions (WGS)

WGS has become increasingly cost-effective, with the cost per genome dropping below $200 in 2025, making it accessible for clinical use. Recent studies demonstrate that WGS can identify pathogenic variants in 15–25% of previously undiagnosed neurodegenerative cases[@bisbrewer2024]. [@bellenguez2022]

Repeat Expansion Testing

Several neurodegenerative diseases are caused by nucleotide repeat expansions that require specialized testing methods: [@code2023]

| Disease | Gene | Repeat | Pathogenic Threshold |
|---------|------|--------|---------------------|
| Huntington's Disease | HTT | CAG | ≥36 repeats |
| FTD/ALS | C9orf72 | GGGGCC | ≥30 repeats |
| SCA1 | ATXN1 | CAG | ≥39 repeats |
| SCA2 | ATXN2 | CAG | ≥33 repeats |
| SCA3 | ATXN3 | CAG | ≥55 repeats |
| Friedreich's Ataxia | FXN | GAA | ≥66 repeats |
| Myotonic dystrophy | DMPK | CTG | ≥50 repeats |
| FXTAS | FMR1 | CGG | 55–200 (premutation) |
| DRPLA | ATN1 | CAG | ≥48 repeats |

Standard next-generation sequencing often misses large repeat expansions, requiring specialized methods such as repeat-primed PCR, Southern blotting, or long-read sequencing technologies (PacBio, Oxford Nanopore)[@rohilla2019].

APOE Genotyping and Risk Assessment

APOE genotyping plays a unique role in neurodegenerative disease risk assessment, particularly for Alzheimer's Disease. The APOE gene has three common alleles (ε2, ε3, ε4), with ε4 being a major risk factor for late-onset AD[@bellenguez2022].

Clinical Considerations

Risk modification: APOE ε4 carriers have approximately 3-4x increased risk for AD compared to non-carriers, while ε2 carriers may have protective effects
Therapeutic implications: APOE status can influence response to certain therapies, including aducanumab and lecanemab
Interpretation challenges: Many detected variants have unclear clinical effect
Incomplete penetrance: Carrying a pathogenic variant does not guarantee disease
Variable expressivity: The same variant can lead to different phenotypes across individuals
Ancestry bias: Interpretation accuracy varies because reference datasets are uneven across populations
Incidental findings: Broad sequencing can uncover unrelated medically actionable variants

Genetic Counseling

Genetic counseling is essential both before and after genetic testing for neurodegenerative diseases. Pre-test counseling helps patients understand the implications of potential results, including the psychological impact, insurance considerations, and family implications. Post-test counseling aids in result interpretation and planning for the future[@code2023].

External Links

[National Society of Genetic Counselors](https://www.nsgc.org/)
[Genetic Testing Registry - NIH](https://www.ncbi.nlm.nih.gov/gtr/)
[FDA - Genetic Tests](https://www.fda.gov/medical-devices/in-vitro-diagnostics/genetic-tests)
[ClinicalTrials.gov - Genetic Testing](https://clinicaltrials.gov/search?cond=neurodegenerative+diseases&intr=genetic+testing)
[alzheimers](/mechanisms/dopaminergic-neuron-vulnerability)
[huntington](/mechanisms/dopaminergic-neuron-vulnerability)
[ftd](/diseases/frontotemporal-disease)
[als](/diseases/amyotrophic-lateral-sclerosis)
[parkinsons](/genes/park2)
[Genetic Counseling](/mechanisms/dopaminergic-neuron-vulnerability)
[apoe](/genes/apoe)
[GeneTests](https://www.genetests.org/) — Medical genetics information resource
[PDGene Database](https://www.pdgene.org/) — Parkinson's Disease gene database
[ALS Online Genetics Database](https://alsod.iop.kcl.ac.uk/) — ALS gene variant database

Background

The study of Genetic Testing For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Goldman JS, et al, Genetic testing and genetic counseling for Alzheimer's Disease (2023)

Apostolova LG, et al, Genetic testing and genetic counseling for Alzheimer's Disease: Practice trends and future directions (2024)

Koriath C, et al, Genetic testing in dementia: A practical guide (2021)

Bis-Brewer J, et al, Whole-genome sequencing in neurodegenerative diseases (2024)

Rohilla S, et al, Repeat expansion detection in neurodegenerative diseases (2019)

Bellenguez C, et al, APOE and Alzheimer's disease: Genetics, pathophysiology and therapeutic implications (2022)

Code P, et al, Genetic counseling for neurodegenerative diseases: Current practices and future directions (2023)

Pathway Diagram

The following diagram shows the key molecular relationships involving Genetic Testing for Neurodegenerative Diseases discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →